Linaclotide

Brand names: Linzess · Active ingredient: Linaclotide

In short: LINZESS is indicated for the treatment of: • irritable bowel syndrome with constipation (IBS-C) in adults and pediatric patients 7 years of age and older • chronic idiopathic constipation (CIC) in adults • functional constipation (FC) in pediatric patients 2 years of age and older

Forms & strengthsLINZESS capsules are white to off-white opaque: 72 mcg; gray imprint “FL 72” 145 mcg; gray imprint “FL 145” 290 mcg; gray imprint “FL 290”
LabelAllergan, Inc.
Label updatedOct 19, 2026

What is Linaclotide used for?

LINZESS is indicated for the treatment of:

• irritable bowel syndrome with constipation (IBS-C) in adults and pediatric patients 7 years of age and older

• chronic idiopathic constipation (CIC) in adults

• functional constipation (FC) in pediatric patients 2 years of age and older

⚠ Boxed warning (FDA's strongest warning)

LINZESS is contraindicated in patients less than

2

years of age; in nonclinical studies in neonatal mice, administration of a single, clinically relevant adult oral dose of linaclotide caused deaths due to dehydration

[see Contraindications (

4

), Warnings and Precautions (

5.1

), Use in Specific Populations (

8.4

)]

.

Linaclotide dosage

Irritable Bowel Syndrome with Constipation (IBS-C)

:

The recommended dosage of LINZESS is:

• Adults: 290 mcg orally once daily

• Pediatric patients 7 years of age and older: 145 mcg orally once daily

Chronic Idiopathic Constipation (CIC)

in

Adults

The recommended dosage of LINZESS in adults is 145 mcg orally once daily. A dosage of 72 mcg once daily may be used based on individual presentation or tolerability.

Functional Constipation (FC) in

Pediatric Patients

2

Years

of

Age and Older

The recommended dosage of LINZESS in pediatric patients 2 years of age and older is 72 mcg orally once daily.

Take LINZESS on an empty stomach, at least 30 minutes prior to a meal at approximately the same time each day.

If a dose is missed, skip the missed dose and take the next dose at the regular time. Do not take 2 doses at the same time.

Do not crush or chew LINZESS capsule or capsule contents.

Swallow LINZESS capsule whole.

For patients who are unable to swallow the capsule whole, LINZESS capsules can be opened and administered orally in either applesauce or with water or administered with water via a nasogastric or gastrostomy tube. Sprinkling of LINZESS beads on other soft foods or in other liquids has not been tested.

Oral Administration in Applesauce

Place one teaspoonful of room-temperature applesauce into a clean container.

Open the capsule.

Sprinkle the entire contents (beads) on applesauce.

Consume the entire contents immediately. Do not chew the beads. Do not store the bead-applesauce mixture for later use.

Oral Administration in Water

Pour approximately 30 mL of room-temperature bottled water into a clean cup.

Open the capsule.

Sprinkle the entire contents (beads) into the water.

Gently swirl beads and water for at least 20 seconds.

Swallow the entire mixture of beads and water immediately.

Add another 30 mL of water to any beads remaining in cup, swirl for 20 seconds, and swallow immediately.

Do not store the bead-water mixture for later use.

Note: The drug is coated on the surface of the beads and will dissolve off the beads into the water. The beads will remain visible and will not dissolve. Therefore, it is not necessary to consume all the beads to deliver the complete dose.

Administration with Water via a Nasogastric or Gastrostomy Tube

Open the capsule and empty the beads into a clean container with 30 mL of room-temperature bottled water.

Mix by gently swirling beads for at least 20 seconds.

Draw-up the beads and water mixture into an appropriately sized catheter-tipped syringe and apply rapid and steady pressure (10 mL/10 seconds) to dispense the syringe contents into the tube.

Add another 30 mL of water to any beads remaining in the container and repeat the process. …

How to take Linaclotide — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Medication Guide).

Advise patients:

Diarrhea

To stop LINZESS and contact their healthcare provider if they experience unusual or severe abdominal pain, and/or severe diarrhea, especially if in combination with hematochezia or melena .

Accidental Ingestion

Accidental ingestion of LINZESS in children especially in patients less than 2 years of age may result in severe diarrhea and dehydration. Instruct patients to take steps to store LINZESS securely and out of reach of children, and to dispose of unused LINZESS

.

Administration

and Handling

Instructions

To take LINZESS once daily on an empty stomach at least 30 minutes prior to a meal at approximately the same time each day .

If a dose is missed, skip the missed dose and take the next dose at the regular time. Do not take 2 doses at the same time.

To swallow LINZESS capsules whole. Do not crush or chew capsules or capsule contents. …

Warnings & precautions

Do not take this medicine if: LINZESS is contraindicated in:

Patients less than 2 years of age due to the risk of serious dehydration

.

Patients with known or suspected mechanical gastrointestinal obstruction.

LINZESS is contraindicated in patients less than 2 years of age. In neonatal mice (human age equivalent of approximately 0 to 28 days), linaclotide increased fluid secretion as a consequence of age-dependent elevated GC-C agonism which was associated with increased mortality within the first 24 hours due to dehydration. There was no age-dependent trend in GC-C intestinal expression in a clinical study of children 2 to less than 18 years of age; however, there are insufficient data available on GC-C intestinal expression in children less than 2 years of age to assess the risk of developing diarrhea and its potentially serious consequences in these patients

.

In adults, diarrhea was the most common adverse reaction of LINZESS-treated patients in the pooled IBS-C and CIC double-blind placebo-controlled trials. The incidence of diarrhea was similar between the IBS-C and CIC populations. Severe diarrhea was reported in 2% of adult patients with IBS-C or CIC treated with LINZESS 145 mcg or 290 mcg once daily, and in <1% of adult patients with CIC treated with LINZESS 72 mcg once daily .

In pediatric patients, diarrhea was also the most common adverse reaction in clinical trials of patients 7 to 17 years of age with IBS-C and 6 to 17 years of age with FC treated with LINZESS .

• In a double-blind trial of patients 7 to 17 years of age with IBS-C, diarrhea was reported in 7% and 8% of patients treated with LINZESS 145 mcg and 290 mcg once daily, respectively. One severe case of diarrhea was reported in the IBS-C trial at a dosage higher than the recommended LINZESS 145 mcg once daily dosage for IBS-C. …

Linaclotide side effects

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Demographic characteristics were comparable between treatment groups in all studies .

Irritable Bowel Syndrome with Constipation (IBS-C)

in Adults

Most Common Adverse Reactions

The data described below reflect exposure to LINZESS in the two placebo-controlled clinical trials involving 1605 adult patients with IBS-C (Trials 1 and 2) . Patients were randomized to receive placebo or 290 mcg LINZESS once daily on an empty stomach for up to 26 weeks. Table 1 provides the incidence of adverse reactions reported in at least 2% of IBS-C patients in the LINZESS treatment group and at an incidence that was greater than in the placebo group.

Adverse Reactions | LINZESS

290 mcg

[N=807]

% | Placebo

[N=798]

%

Gastrointestinal

Diarrhea Abdominal painb

Flatulence Abdominal distension | 20742 | 3521

Infections and Infestations

Viral Gastroenteritis | 3 | 1

Nervous System Disorders

Headache | 4 | 3

a:

Reported in at least 2% of LINZESS-treated patients and at an incidence greater than placebo

b: “Abdominal pain” term includes abdominal pain, upper abdominal pain, and lower abdominal pain. …

About this medicine

LINZESS (linaclotide) is a guanylate cyclase-C (GC-C) agonist. Linaclotide is a 14-amino acid peptide with the following chemical name: L-cysteinyl-L-cysteinyl-L-glutamyl-L-tyrosyl-L-cysteinyl-L-cysteinyl-L-asparaginyl-L-prolyl-L-alanyl-L-cysteinyl-L-threonyl-glycyl-L-cysteinyl-L-tyrosine, cyclic (1-6), (2-10), (5-13)-tris (disulfide).

The molecular formula of linaclotide is C59H79N15O21S6 and its molecular weight is 1526.8. The amino acid sequence for linaclotide is shown below:

Linaclotide is an amorphous, white to off-white powder. It is slightly soluble in water and aqueous sodium chloride (0.9%). LINZESS contains linaclotide-coated beads in hard gelatin capsules. LINZESS is available as 72 mcg, 145 mcg and 290 mcg capsules for oral administration.

The inactive ingredients of LINZESS 72 mcg capsules include: calcium chloride dihydrate, L-histidine, microcrystalline cellulose, polyvinyl alcohol, and talc. The components of the capsule shell include gelatin and titanium dioxide. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 09beda19-56d6-4a56-afdc-9a77b70b2ef3. Read the full official label on DailyMed.

Related medicines

Omeprazole Pantoprazole Fluoxetine Amoxicillin Famotidine Ondansetron Esomeprazole Docusate